Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

Abstract: Method for the detection of Chlamydia trachomatis, which method comprises the performance of a DNA amplification involving the use of a primer pair by using DNA that is derived from a sample as a template and the detection of an amplification product, characterized in that the primer pair used for the DNA amplification is designed on the basis of nucleotide sequences of the regions corresponding to the nucleotide numbers 3654 to 4320 and 4351 to 4448 in the nucleotide sequence of SEQ ID No. 1.

Abstract: The invention disclosed herein relates to methods and means for allocating, allotting, apportioning, dispensing, distributing, preparing, portioning, meting out and/or otherwise providing, controlling and/or regulating access to quantities of foods, beverages, and/or other substances. Various embodiments of the methods and means of the invention may be performed by and/or implemented in hardware, in software, by one or more entities, and/or by some combination of hardware, software and/or one or more entities.

Abstract: The present invention provides isotopically labeled deoxy-glucose and derivatives thereof, methods of their preparation, ration, kits comprising them and uses thereof for spin hyperpolarized magnetic resonance imaging, utilized in the quantitative and qualitative diagnosis of states, conditions, diseases, or disorders in the body of a subject.

Abstract: Novel derivatives of tris(2-hydroxyphenyl)methanes which have, as functional groups, polyalkoxy groups unmodified or modified with terminal hydrophilic groups, preparation of such compounds and use thereof, especially for mineral oil production.

Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Abstract: An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation.

Abstract: An outer layer material having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. Prior to intermingling with the guest, a host blend may be produced to include a physical blend of a hydrophobic polymer host and a maleated hydrophobic co-host (preferably, an anhydride functionalized hydrophobic polymer, whereby the polymer so functionalized, is the same as that selected for the host). The intermingling of the guest and host, or host-co-host blend, includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between.

Abstract: The present invention provides a compound represented by the following formula (1): wherein X1 and X2 each independently represent a hydrogen atom or a hydroxyl-protecting group; Y represents a C7-20 aralkyl group which may optionally have one or more substituents selected from a halogen atom, a lower alkyl group or a lower alkoxy group; and Z represents a halogen atom, a C1-4 alkylthio, or an arylthio group, or its corresponding sulfoxide group.

Abstract: Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.

Abstract: The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.

Abstract: An object of the present invention is to provide a composition having the effect of suppressing matrix metalloproteinase activity. Specifically, the present invention relates to a composition suppressing matrix metalloproteinase activity containing a glycolysis inhibitor as an active ingredient.

Abstract: Thermostable enzyme technology for algal bioconversion The present invention relates to thermostable enzyme systems suitable for use in the production of biofuels and bio-products from algae, and to a method of producing energy feedstocks, stocks, specifically (i) fermentable sugars and (ii) lipid fractions from algae, for the production of biofuels such as bioethanol, biobutanol and bio-oils or biodiesel, as well as other value-added biomolecules (e.g. proteins, peptides, oils, pigments, nucleic acids).

Abstract: Dithioamine reducing agents useful for the reduction of disulfide bonds. The reducing agents of this invention are useful, for example, to reduce disulfide bonds, particularly in proteins, or to prevent the formation of disulfide bonds, particularly in proteins and other biological molecules. Reducing agents of this invention are useful and suitable for application in a variety of biological applications, particularly as research and synthetic reagents. The invention provides S-acylated dithioamines which can be selectively activated reducing agents by removal of the S-acyl groups enzymatically or chemically. The invention further provides dithiane precursors of thioamino reducing agents. The invention provides dithioamine reducing agents, S-acylated dithioamines and dithianes which are immobilized on surfaces, including among others, glass, quartz, microparticles, nanoparticles and resins.

Abstract: Methods for the production of an intergeneric hybrid plants and plants produced thereby. In certain aspects, intergeneric hybrid plants are produced by crossing a sorghum parent plant comprising a mutant sorghum iap allele with a second moncot plant. Methods for the use of such plants and products obtained therefrom are also provided.

Abstract: Oligonucleotides targeted to HPV Type 16 and/or Type 18 nucleic acid sequences which are particularly useful to aid in detecting HPV type 16 and or 18 are described. The oligonucleotides can aid in detecting HPV Type 16 and/or Type 18 in different ways such as by acting as hybridization assay probes, helper probes, and/or amplification primers.

Abstract: A cellular constituent is lysed from, produced by and/or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and/or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory response.

Abstract: Object: To provide a composition for preventing periodontal diseases (prophylactic agent of periodontal diseases), the composition having an excellent cariostatic property, being safe and stable for prolonged use and having less effects on flavor. Means for Resolution: A non-cariogenic material prepared by blending a rare sugar in the D form as selected from the group consisting of D-psicose, D-sorbose and D-tagatose, a rare sugar in the L form as selected from L-fructose, L-psicose and L-tagatose, or allitol as a rare sugar derivative, singly or in combination. A cariostatic agent comprising D-psicose, D-sorbose, D-tagatose, L-fructose, L-psicose and/or L-tagatose. A cariostatic agent in combination with catechins.

Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.

Abstract: The present invention relates to a method for dissolving cellulose. The method comprises—introducing cellulosic raw material,—treating the cellulosic raw material in an enzymatic treatment process,—mixing the cellulosic raw material after the enzymatic treatment in an aqueous solution in order to obtain an aqueous intermediate product containing the cellulosic raw material of at least 3.5 wt.-%, alkali metal hydroxide between 3.5 wt.-% and 7 wt.-% and zinc salt,—freezing the intermediate product to a solid state, and—melting the frozen intermediate product. The present invention also relates to a cellulosic product obtained from a solution comprising dissolved cellulose.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, for use in the prevention and treatment of diseases including diabetes.

Abstract: Fluorescent phenyl xanthene dyes are described that comprise any fluorescein, rhodamine or rhodol comprising a particular C9 phenyl ring. One or both of the ortho groups on the lower C9 phenyl ring is ortho substituted with a group selected from alkyl, heteroalkyl, alkoxy, halo, haloalkyl, amino, mercapto, alkylthio, cyano, isocyano, cyanato, mercaptocyanato, nitroso, nitro, azido, sulfeno, sulfinyl, and sulfino. In one embodiment, halo and/or hydroxy groups are used. Optimal dyes contain a lower C9 phenyl ring in which both ortho groups are the same and the lower ring exhibits some form a symmetry relative to an imaginary axis running from the phenyl rings point of attachment to the remainder of the xanthene dye through a point para to the point of attachment. The phenyl xanthene dyes may be activated. Furthermore, the phenyl xanthene dyes may be conjugated to one or more substances including other dyes.

Abstract: Polymers useful as catalysts in non-enzymatic saccharification processes are provided. Provided are also methods for hydrolyzing cellulosic materials into monosaccharides and/or oligosaccharides using these polymeric acid catalysts.

Abstract: Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing.

Abstract: Oil based emulsifiable concentrates containing a liquid saccharide including a) at least one oil component; b) at least one saccharide, particularly a liquid saccharide solution (LS); c) and at least one non-ionic surfactant. The concentrate may also contain at least one of d) at least one surfactant hydrocarbyl saccharide; or e) at least one anionic surfactant; or f) at least one additional oil soluble non-ionic surfactant. The concentrates are typically homogeneous for at least 24 hours and emulsify readily on dilution into water. The concentrates may also contain an antifoaming agent especially a polysiloxane. Upon dilution in water, the emulsions formed from the concentrates are applied to substrates in combination with agrochemically active ingredients, preferably N-phosphonomethylglycine in the form of its soluble salts, to control weeds.

Abstract: Oil based emulsifiable concentrates containing a liquid saccharide including a) at least one oil component; b) at least one saccharide, particularly a liquid saccharide solution (LS); c) and at least one non-ionic surfactant. The concentrate may also contain at least one of d) at least one surfactant hydrocarbyl saccharide; or e) at least one anionic surfactant; or f) at least one additional oil soluble non-ionic surfactant. The concentrates are typically homogeneous for at least 24 hours and emulsify readily on dilution into water. The concentrates may also contain an antifoaming agent especially a polysiloxane. Upon dilution in water, the emulsions formed from the concentrates are applied to substrates in combination with agrochemically active ingredients, preferably N-phosphonomethylglycine in the form of its soluble salts, to control weeds.

Abstract: The present invention provides a therapeutic agent for anaerobic diseases such as solid tumor, comprising in combination a pharmaceutical composition for the treatment of an anaerobic disease containing the transformed anaerobic microorganism as an active component and a pharmaceutical composition containing as an active component an anaerobic microorganism colonization and growth enhancer for enhancing the specific colonization and proliferation of the anaerobic microorganism at an anaerobic disease site. Furthermore, the present invention provides to an anaerobic microorganism colonization and growth enhancer for enhancing colonization and growth of the transformed anaerobic microorganism at a disease site that is in an anaerobic environment.

Abstract: The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.

Abstract: The present invention provides an immunogenic composition comprising a T-cell antigen in association with a rhamnose monosaccharide and/or Forssman disaccharide, and corresponding methods for inducing immune response. The T-cell antigen may be for example, a tumor vaccine, such as a tumor cell or one or more tumor antigens. The invention takes advantage of the naturally high titers of anti-Rhamnose and/or anti-Forssman disaccharide in humans to target vaccine compositions to antigen presenting cells.

Abstract: An emulsion contains a saccharide siloxane copolymer as an emulsifier. The emulsion is useful in formulating personal care products.

Abstract: A method by which high-purity CMP-N-acetylneuraminic acid (HPLC purity, 95% or higher), which has been difficult to obtain with any technique other than chromatography, can be easily obtained in satisfactory yield by a simple operation without the need of chromatography. The process, which is for producing high-purity CMP-N-acetylneuraminic acid (CMP-NeuAc), is characterized by conducting a suitable combination of the following steps (1) to (4). Step 1: a step in which divalent cations are added to a solution containing CMP-NeuAc to thereby precipitate the phosphoric acid, pyrophosphoric acid, and nucleotide which coexist; Step 2: a step in which a phosphatase is added to a solution containing CMP-NeuAc to thereby convert the coexistent nucleotide into nucleoside; Step 3: a step in which an organic solvent is added to precipitate the CMP-NeuAc; and Step 4: a step in which the CMP-NeuAc precipitated is recovered.

Abstract: Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.

Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.

Abstract: Cement compositions comprising carboxylated inulin and methods of using the same to cement a workspace. In one embodiment, a method of cementing includes providing a cement composition comprising a carboxylated inulin, for example, in a subterranean formation. The method further includes allowing the cement composition to set. In some embodiments, the cement composition has a thickening time of from about 2 hours to about 11 hours. In other embodiments, the cement composition has a viscosity that is about constant for a period of time after the cement composition is placed.

Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.

Abstract: Provided are various compounds comprising the formula Also provided are fluorescent dyes comprising the above compound. Additionally, a fluorescence energy transfer system is provided that comprises the above-described fluorescent dye and a second dye, wherein the second dye is capable of energy transfer with the fluorescent dye. Further provided is a kit for labeling a target molecule, where the kit comprises the above-described fluorescent dye with additional reagents useful for labeling the target molecule. Additionally provided is a target molecule labeled with the above-described fluorescent dye. A method of labeling a target molecule is also provided. The method comprises contacting reactive group Z of the above-described fluorescent dye with the target molecule such that reactive group Z reacts with the target molecule to form a covalent bond between reactive group Z and the target molecule. Also, another method of labeling a target molecule is provided.

Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.

Abstract: A method is disclosed for synthesizing 2?,3?-didehydro-2?,3?-dideoxynucleosides (d4Ns) from a nucleophile-mediated elimination, such as a telluride-mediated elimination reaction. After substitution of 2,2?-anhydronucleosides with a nucleophile, such as a telluride monoanion, a telluride intermediate is formed, and its elimination leads to formation of the olefin products (d4Ns). This disclosure describes this telluride-assisted (or nucleophile-assisted) reaction and how to facilitate the substitution and elimination in order to form d4Ns.

Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

Abstract: Intrauterine Fetal Growth Restriction (IUGR) is a very important clinical problem for which no satisfactory treatment is available so far. The current invention of intravenous (IV) hypertonic glucose supplementation to the mother to improve the glucose transfer to the fetus at the intervillous space by improved facilitated diffusion can be a safe and easy way of treating this problem, as the improved fetal blood glucose can lead to fetal lipogenesis that can conserve the fetal O2 (oxygen) utilization and also relieve the associated metabolic derangements of fetal hypoxia, hypercapnia, and acidosis, apart from replenishing the oxidized coenzymes needed for the carbohydrate metabolism. The use of trans-amniotic fetal feeding studied by animal experiments can be difficult in humans, because of the danger of infection, which can be overcome by the use of implantable ports with a sterile patch technique.

Abstract: Degradable complexes comprising a polycation, a polyanion and a polynucleotide are useful for in vivo polynucleotide delivery applications.

Abstract: Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Abstract: The invention discloses a method for detection of genetically modified maize BT11. The principle of the method is that the DNA template of the sample is amplified at a temperature of 63° C.˜65° C. for 45˜60 min by using 4 specific primers and a DNA polymerase with strand displacement activity. The identification thereof is to make a judgment on whether BT11 component is contained in the sample by directly observing the turbidity in the reaction tube or the color change after the addition of SYBR Green with naked eyes or by agarose gel electrophoresis. The detection method of the invention has the advantages of high specificity, quickness, simplicity and convenience and the like, which provides a convenient method for detection of genetically modified maize BT11 with an extensive application prospect.

Abstract: The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of R5 and R6 are selected from the following: (1) R5=R6=Me; (2) R5=Me, R6=OMe; (3) R5=Me, R6=H; (4) R5=Me, R6=F; (5) R5=F, R6=H; and (6) R5=OMe, R6=H.

Abstract: Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.

Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

Abstract: Lignin polymers having distinctive properties, including a generally high molecular weight and generally homogeneous size distribution, as well as preservation of native reactive side groups, are isolated by solvent extraction of plant materials. Methods for isolation of lignin polymers, and for use of the isolated lignin polymers are disclosed. Compositions containing lignin isolated from plant materials, such as carbon fiber composites, resins, adhesive binders and coatings, polyurethane-based foams, rubbers and elastomers, plastics, films, paints, nutritional supplements, food and beverage additives are disclosed. Xylose and xylose derivatives, furfural, fermentable sugars, cellulose and hemi-cellulose products may be used directly or further processed. The lignin polymers and other plant-derived products disclosed herein may be produced in abundance at low cost, and may be used as substitutes for feedstocks originating from fossil fuel or petrochemical sources in the manufacture of various products.

Abstract: A lifespan extending agent that is safe for animals, and can easily be ingested in a form that resembles foods. A lifespan extending method is also disclosed. In the lifespan extending agent, a rare sugar usable as a sweetener is contained as an active ingredient.